MPX Bioceutical Corporation (CSE: MPX) (OTC: MPXEF) - Investor Dashboard

MPX Bioceutical Corp
CSE Symbol: MPX
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: 83
Established: 1974
CEO: Scott Boyes

MPX Bioceutical Corporation – Management & Advisory Team

Scott Boyes – President & CEO

W. Scott Boyes is the President, Chief Executive Officer and a director of the Corporation and devotes 100% of his time towards the business of the Corporation as an employee of the Corporation. His responsibilities include leadership of the Corporation, including, but not limited to, the general management, strategy and expansion of the BCC Corporate Group. Mr. Boyes sits on the Corporation’s Audit Committee and Corporate Governance and Nominating Committee.

Mr. Boyes is a seasoned senior executive with diversified and cross-functional experience, combining MBA credentials with a strong career background in revenue development and general management. Prior to the CGX Acquisition, Mr. Boyes was President of CGX where he focused on general management of CGX. Since August, 2008, Mr. Boyes has been President of NCD Associates, where he focused his consulting services on financial restructuring, and revenue enhancement and streamlining business processes for distressed or high growth companies. In 2005, Mr. Boyes founded and developed Railcrew Xpress Corporation, a specialized passenger transportation company servicing U.S. railroads, and served as its President until 2008. There, he developed and led the sales and customer service teams, managed the acquisition and integration of three competitor companies and developed and deployed sophisticated dispatch, tracking and reporting technology. From 2000 to 2005, Mr. Boyes served as President and Chief Executive Officer of Hallcon Corporation where he was responsible for the senior executive management of the company and its operating subsidiaries. Previously, he served as a Vice President a large Canadian Bank and Vice President and General manager of a business unit within a multinational commercial finance company always with a focus on marketing and revenue development.

Randall  Stafford – CFO

Randall G. Stafford is the Chief Financial Officer and a director of the Corporation and devotes approximately 10% of his time towards the business of the Corporation as an employee of the Corporation. Mr. Stafford’s responsibilities include all financial and accounting matters including preparation of interim and annual financial statements, continuous disclosure filing requirements and filing corporate tax returns. Mr. Stafford sits on the Corporation’s Compensation Committee.

Mr. Stafford is was the Vice President of Finance, Cushman & Wakefield, Inc., the world’s largest privately owned international commercial real estate firm, between June, 2014 and July, 2016. Previously, Mr. Stafford was a realtor at Royal LePage Real Estate Service Ltd., Johnston & Daniel Division, Brokerage between November 2013 and June 2014 and continues to hold his real estate licence in the Province of Ontario. Mr. Stafford was the Director of Operations and Fulfillment, First Canadian Title, one of Canada’s largest providers of title insurance and backend processing operations for residential and commercial real estate transactions, a division of one of the world’s largest title insurance providers, First American Title Company, between November 2010 and February 2013.

Mr. Stafford received an Masters of Business Administration from Rotman School of Business at the University of Toronto, and holds his Certified Management Accountant and Chartered Professional Accountant designations.

Beth Stavola – President CGX (U.S. Operations)

Elizabeth M. Stavola is the President of CGX and devotes 90% of her time towards the business of the Corporation as an employee of CGX. Her responsibilities include managing all of CGX’s operations in the United States.

Ms. Stavola the founder of Stavola Medical Marijuana Holdings, Health for Life Inc., GreenMart of Nevada, GreenMart of Maryland, Elemental Health Group of Pennsylvania, and CBD For Life. She has been the driving force behind the development of these thriving cannabis businesses into profitable, strong brands. Prior to her successful career in the cannabis industry, Ms. Stavola was a senior Wall Street executive, where she spent most of her career at Jefferies and Company, most recently as Senior Vice President, Institutional Equity Sales.

In 1992, Ms. Stavola received a Bachelor of Science in Finance and Economics from Monmouth University.

Marilyn Bloovol – Chairman of the Board

Corporate and securities lawyer with 35 years of experience in financing, mergers and acquisitions, negotiating and structuring transactions and regulatory compliance for corporations and financial review. She has served as an officer, director and corporate counsel to numerous public and private companies.

David Layman – Independent Director

yman – Independent Director  Independent Director at RJK Explorations Ltd., Chief Financial Officer & Vice President at Diadem Resources Ltd., President at Atlantic Settlement Holdings Corp., and President at Deux Freres Ltd.

Donald P. Stott – Director

Donald P. Stott is a Director of the Corporation where he sits on the Corporation’s Audit Committee and Corporate Governance and Compensation committee. Mr. Stott retired in June 1996 after a career as a stock broker for over 18 years, and as a financial consultant for both private and public companies.

Significant Insider Ownership

CEO Scott Boyes
3.9mm shares, 3.5mm options at $0.20

Chairperson Marilyn Bloovol
2.7mm shares

President, U.S. Operations Beth Stavola
3.5mm options each at $0.20, $0.60 and $1.00

Hi-Med LLC
25.73mm shares

Naser Bin Butti Almheiri
52.5mm shares

Visit MPX Bioceutical Corporation,

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. MPX Bioceutical Corporation is a client of NCV Media, LLC. Read our full disclaimer.